Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Tempol by DMK Pharmaceuticals for Radiodermatitis: Likelihood of Approval
Tempol is under clinical development by DMK Pharmaceuticals and currently in Phase II for Radiodermatitis. According to GlobalData, Phase II...